Almac Group, a global contract pharmaceutical development and manufacturing organization, has been awarded $200,000 by the Bill & Melinda Gates Foundation (BMGF) to develop novel biosynthetic routes with the goal of substantially lowering the cost of selected steroidal Active Pharmaceutical Ingredients (APIs) and enable their use in developing world aid programs.   Almac’s biocatalysis experts based in Ireland will work to develop novel biocatalytic routes to Etonorgestrel and Levonorgestrel...